A detailed history of Emerald Advisers, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 1,577 shares of ALNY stock, worth $386,191. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,577
Previous 1,618 2.53%
Holding current value
$386,191
Previous $393,000 10.18%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$233.81 - $287.01 $9,586 - $11,767
-41 Reduced 2.53%
1,577 $433,000
Q2 2024

Aug 06, 2024

SELL
$143.31 - $247.0 $64,776 - $111,644
-452 Reduced 21.84%
1,618 $393,000
Q1 2024

May 08, 2024

SELL
$146.51 - $198.2 $3,516 - $4,756
-24 Reduced 1.15%
2,070 $309,000
Q4 2023

Feb 05, 2024

SELL
$151.41 - $196.57 $140,054 - $181,827
-925 Reduced 30.64%
2,094 $400,000
Q3 2023

Oct 26, 2023

SELL
$170.77 - $211.65 $11,441 - $14,180
-67 Reduced 2.17%
3,019 $534,000
Q2 2023

Jul 25, 2023

SELL
$185.01 - $212.05 $8,510 - $9,754
-46 Reduced 1.47%
3,086 $586,000
Q1 2023

May 04, 2023

BUY
$182.66 - $235.53 $105,029 - $135,429
575 Added 22.49%
3,132 $627,000
Q4 2022

Feb 03, 2023

SELL
$185.53 - $241.31 $7,977 - $10,376
-43 Reduced 1.65%
2,557 $607,000
Q3 2022

Oct 25, 2022

SELL
$138.54 - $232.0 $2,909 - $4,872
-21 Reduced 0.8%
2,600 $520,000
Q2 2022

Jul 29, 2022

SELL
$120.42 - $169.29 $37,932 - $53,326
-315 Reduced 10.73%
2,621 $382,000
Q1 2022

Apr 29, 2022

SELL
$127.18 - $173.91 $6,867 - $9,391
-54 Reduced 1.81%
2,936 $479,000
Q4 2021

Feb 02, 2022

SELL
$159.56 - $209.29 $6,701 - $8,790
-42 Reduced 1.39%
2,990 $507,000
Q3 2021

Oct 28, 2021

SELL
$169.75 - $207.73 $179,425 - $219,570
-1,057 Reduced 25.85%
3,032 $572,000
Q1 2021

Apr 29, 2021

SELL
$126.83 - $175.69 $22,829 - $31,624
-180 Reduced 4.22%
4,089 $577,000
Q4 2020

Jan 29, 2021

SELL
$122.97 - $147.0 $414,408 - $495,390
-3,370 Reduced 44.12%
4,269 $555,000
Q3 2020

Oct 28, 2020

SELL
$121.19 - $165.49 $10,907 - $14,894
-90 Reduced 1.16%
7,639 $1.11 Million
Q2 2020

Jul 28, 2020

SELL
$104.21 - $156.44 $150,583 - $226,055
-1,445 Reduced 15.75%
7,729 $1.15 Million
Q1 2020

Apr 30, 2020

SELL
$93.12 - $133.99 $10,336 - $14,872
-111 Reduced 1.2%
9,174 $999,000
Q4 2019

Jan 29, 2020

SELL
$74.51 - $124.23 $103,196 - $172,058
-1,385 Reduced 12.98%
9,285 $1.07 Million
Q3 2019

Oct 31, 2019

SELL
$70.9 - $87.82 $105,924 - $131,203
-1,494 Reduced 12.28%
10,670 $858,000
Q2 2019

Jul 31, 2019

SELL
$65.86 - $92.79 $72,050 - $101,512
-1,094 Reduced 8.25%
12,164 $883,000
Q1 2019

May 01, 2019

BUY
$72.76 - $93.45 $5,311 - $6,821
73 Added 0.55%
13,258 $1.24 Million
Q4 2018

Jan 30, 2019

SELL
$62.67 - $88.33 $315,418 - $444,564
-5,033 Reduced 27.63%
13,185 $961,000
Q3 2018

Oct 31, 2018

BUY
$87.52 - $122.67 $42,272 - $59,249
483 Added 2.72%
18,218 $1.59 Million
Q2 2018

Jul 31, 2018

BUY
$88.31 - $107.8 $341,583 - $416,970
3,868 Added 27.89%
17,735 $1.75 Million
Q1 2018

Apr 26, 2018

SELL
$115.92 - $148.54 $115,456 - $147,945
-996 Reduced 6.7%
13,867 $1.65 Million
Q4 2017

Feb 05, 2018

SELL
$114.49 - $139.98 $106,475 - $130,181
-930 Reduced 5.89%
14,863 $1.89 Million
Q3 2017

Oct 30, 2017

BUY
$72.53 - $118.27 $1.15 Million - $1.87 Million
15,793
15,793 $1.86 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.